• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form POS AM filed by Venus Concept Inc.

    2/6/26 4:29:36 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care
    Get the next $VERO alert in real time by email
    POS AM 1 ef20064995_posam.htm POS AM
    As filed with the U.S. Securities and Exchange Commission on February 6, 2026

    Registration No. 333-236207
    Registration No. 333-237737
    Registration No. 333-252562
    Registration No. 333-260267
    Registration No. 333-262160
    Registration No. 333-268863
    Registration No. 333-273251
    Registration No. 333-275862
    Registration No. 333-278561
    Registration No. 333-282811


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-236207
    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-237737
    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-252562
    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-260267
    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-262160
    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-268863
    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-273251
    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-275862
    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-278561
    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-282811

    FORM S-3
    REGISTRATION STATEMENT
    UNDER

    THE SECURITIES ACT OF 1933
     
    VENUS CONCEPT INC.
    (Exact name of registrant as specified in its charter)

    Delaware
    3841
    06-1681204
    (State or other jurisdiction of incorporation or organization)
    (Primary Standard Industrial Classification Code Number)
    (I.R.S. Employer Identification Number)

    235 Yorkland Blvd, Suite 900
    Toronto, Ontario M2J 4Y8
    (877) 848-8430

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

    Michael Mandarello
    Chief Legal Officer & Head of Strategy & Operations
    Venus Concept Inc.
    235 Yorkland Blvd., Suite 900
    Toronto, Ontario M2J 4Y8
    (877) 848-8430

    (Name, address, including zip code, and telephone number, including area code, of agent for service)
     
    With copies to:
    Richard Raymer
    Dorsey & Whitney LLP
    66 Wellington St. W, Suite 3400
    Toronto, ON M5K 1E6, Canada
    416 367-7388

    Approximate date of commencement of proposed sale to the public: This post-effective amendment is being filed to deregister all of the unsold securities previously registered under the Registration Statements.

    If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box: ☐

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. ☐

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

    If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

    If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer
    ☐
    Accelerated filer
    ☐
    Non-accelerated filer
    ☒
    Smaller reporting company
    ☒


    Emerging growth company
    ☐



    EXPLANATORY NOTE

    DEREGISTRATION OF UNSOLD SECURITIES

    These post-effective amendments relate to the following Registration Statements of Venus Concept Inc. (the “Company”) on Form S-3 (collectively, the “Registration Statements”):


    •
    Registration Statement on Form S-3 (File No. 333-236207) filed with the Securities and Exchange Commission on January 31, 2020 and declared effective on February 12, 2020, registering the offer and sale of up to 99,262 shares of common stock, $0.001 par value per share (“Common Stock”), which includes (i) 75,492 shares of Common Stock and (ii) 23,770 shares of Common Stock issuable upon exercise of certain outstanding warrants to purchase Common Stock (after giving effect to the 1-for-11 reverse stock split of the Common Stock effective on March 4, 2025 (the “2025 Reverse Stock Split”) and the 1-for-15 reverse stock split of the Common Stock effective on May 11, 2023 (the “2023 Reverse Stock Split,” and together with the 2025 Reverse Stock Split, the “Reverse Stock Splits”)), from time to time in one or more offerings by the selling securityholders named therein


    •
    Registration Statement on Form S-3 (File No. 333-237737) filed with the Securities and Exchange Commission on April 17, 2020 and declared effective on May 14, 2020, registering the offer and sale of up to 94,395 shares of Common Stock, which includes (i) 13,940 shares of Common Stock, (ii) 40,000 shares of Common Stock issuable upon conversion of Series A Convertible Preferred Stock, par value $0.0001 per share, and (iii) 40,455 shares of Common Stock issuable upon exercise of certain outstanding warrants to purchase Common Stock (after giving effect to the Reverse Stock Splits), from time to time in one or more offerings by the selling securityholders named therein


    •
    Registration Statement on Form S-3 (File No. 333-252562) filed with the Securities and Exchange Commission on January 29, 2021 and declared effective on February 8, 2021, registering the offer and sale of up to 49,782 shares of Common Stock, issuable upon conversion of the Company’s 8% secured subordinated convertible notes (after giving effect to the Reverse Stock Splits) from time to time in one or more offerings by the selling securityholders named therein


    •
    Registration Statement on Form S-3 (File No. 333-260267) filed with the Securities and Exchange Commission on October 15, 2021 and declared effective on October 25, 2021, registering (A) $55,047,990.59 in aggregate of the following securities (i) common stock, (ii) Preferred Stock, (iii) Debt Securities, (iv) Warrants and (v) units comprised of any of the foregoing securities, (B) the issuance and sale of up to $22,610,490.59 of shares of Common Stock sold to Lincoln Park Capital Fund, LLC pursuant to the purchase agreement, dated as of June 16, 2020 and (C) the offer and sale of up to 31,902 shares of Common Stock, issuable upon exercise of certain outstanding warrants to purchase Common Stock (after giving effect to the Reverse Stock Splits) from time to time in one or more offerings by the selling securityholders named therein


    •
    Registration Statement on Form S-3 (File No. 333-262160) filed with the Securities and Exchange Commission on January 14, 2022, and declared effective on January 24, 2022, registering the offer and sale of up to 82,420 shares of Common Stock, including (a) 59,445 shares of Common Stock and (b) 22,975 shares of Common Stock issuable upon conversion of shares of our nonvoting convertible preferred stock, $0.0001 par value per share (after giving effect to the Reverse Stock Splits), from time to time in one or more offerings by the selling securityholders named therein


    •
    Registration Statement on Form S-3 (File No. 333-268863) filed with the Securities and Exchange Commission on December 19, 2022 and declared effective on December 23, 2022, registering the offer and sale of up to 203,638 shares of Common Stock, including (a) 10,607 shares of Common Stock and (b) 193,031 shares of Common Stock issuable upon conversion of outstanding shares of the Company’s voting convertible preferred stock, $0.0001 par value per share (after giving effect to the Reverse Stock Splits), from time to time in one or more offerings by the selling securityholders named therein


    •
    Registration Statement on Form S-3 (File No. 333-273251) filed with the Securities and Exchange Commission on July 14, 2023, as amended on November 22, 2023, and declared effective on December 20, 2023, registering the offer and sale of up to 189,311 shares of Common Stock, issuable upon conversion of shares of the Company’s senior convertible preferred stock, $0.0001 par value per share (after giving effect to the 2025 Reverse Stock Split), from time to time in one or more offerings by the selling securityholders named therein



    •
    Registration Statement on Form S-3 (File No. 333-275862) filed with the Securities and Exchange Commission on December 1, 2023, and declared effective on December 20, 2023, registering the offer and sale of up to 111,763 shares of Common Stock, issuable upon conversion of outstanding shares of the Company’s Series X Convertible Preferred Stock, $0.0001 par value per share (after giving effect to the 2025 Reverse Stock Split), from time to time in one or more offerings by the selling securityholders named therein


    •
    Registration Statement on Form S-3 (File No. 333-278561) filed with the Securities and Exchange Commission on April 8, 2024, and declared effective on April 17, 2024, registering the offer and sale of up to 149,339 shares of Common Stock, of which 145,339 shares of Common Stock are issuable upon conversion of $2,000,000 in aggregate principal amount of secured subordinated convertible notes (the “Notes”) and 4,120 shares of Common Stock are issuable to pay accrued interest on the Notes as of the date of this registration statement on Form S-3 (File No. 333-278561) (after giving effect to the 2025 Reverse Stock Split) from time to time in one or more offerings by the selling securityholders named therein
     

    •
    Registration Statement on Form S-3 (File No. 333-282811) filed with the Securities and Exchange Commission on October 24, 2024, and declared effective on November 1, 2024, registering up to $30,368,647.94 in aggregate of the following securities (i) common stock, (ii) Preferred Stock, (iii) Debt Securities, (iv) Warrants and (v) units comprised of any of the foregoing securities

    As previously disclosed, on January 20, 2026, the Board of Directors of the Company approved a plan to voluntarily delist the Company’s common stock from the Nasdaq Capital Market, suspend its duty to file periodic reports and other information with the SEC, and terminate its registration of Common Stock under U.S. federal securities laws.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused these post-effective amendments to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Toronto, Province of Ontario, Canada, on February 6, 2026.

    VENUS CONCEPT INC.


    By:

    /s/ Rajiv De Silva
    Name:

    Rajiv De Silva
    Title:

    Chief Executive Officer

    No other person is required to sign this Post-Effective Amendment in reliance upon Rule 478 under the Securities Act of 1933, as amended.



    Get the next $VERO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VERO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VERO
    SEC Filings

    View All

    SEC Form 15-12G filed by Venus Concept Inc.

    15-12G - Venus Concept Inc. (0001409269) (Filer)

    2/9/26 7:15:41 AM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 POS filed by Venus Concept Inc.

    S-8 POS - Venus Concept Inc. (0001409269) (Filer)

    2/6/26 4:47:21 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 POS filed by Venus Concept Inc.

    S-8 POS - Venus Concept Inc. (0001409269) (Filer)

    2/6/26 4:47:21 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    $VERO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Venus Concept Announces Third Quarter 2025 Financial Results

    TORONTO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced financial results for the three and nine months ended September 30, 2025. Summary of Financial Results & Recent Progress: Energy Based Device ("EBD") revenues showing signs of stabilization. Total EBD systems sales of $9.6 million, up 2% year over year Total revenue for the third quarter of $13.8 million, down 8% year-over-year and down 12% quarter-over-quarter. Primarily driven by a decline in the Hair Restoration business (the "Venus Hair Business") impacted by a delay in the pending sale. Third

    11/13/25 7:00:00 AM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    Venus Concept Receives 510(k) for the Venus NOVA, Its Most Advanced Multi-Application Platform for Non-Invasive Body and Skin Treatments

    TORONTO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company"), a global leader in medical aesthetic technology, announced today that it has received a 510(k) clearance from the U.S. Food and Drug Administration ("FDA") to market the Venus NOVA™, the Company's next-generation multi-application platform designed to redefine non-invasive treatments for the body, face, and skin. Venus NOVA integrates Adaptive Electrical Muscle Stimulation (EMS), proprietary (MP)² combining Multi-Polar Radio Frequency (RF) with Pulsed Electromagnetic Fields (PEMF), and Advanced VariPulse™ technology -delivering a powerful, comprehensive solution for body contouring, muscle co

    11/10/25 7:30:00 AM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    Venus Concept Announces $11.48 Million Debt-to-Equity Exchange Transaction

    TORONTO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that, on September 30, 2025, the Company exchanged the full $11.48 million balance of its subordinated convertible notes held by affiliates of Madryn Asset Management, LP ("Madryn") for 545,335 shares of its Series Y preferred stock. Following the transaction, the Company had total debt obligations of approximately $30.1 million, a reduction of 24% compared to $39.7 million outstanding as of December 31, 2024. "Madryn's invaluable partnership has provided us with financial flexibility as we work towards sustained long

    10/2/25 4:05:00 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    $VERO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Large owner Madryn Asset Management, Lp

    4 - Venus Concept Inc. (0001409269) (Issuer)

    10/2/25 7:23:29 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Large owner Madryn Asset Management, Lp

    4 - Venus Concept Inc. (0001409269) (Issuer)

    7/2/25 7:27:23 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Large owner Madryn Asset Management, Lp

    4 - Venus Concept Inc. (0001409269) (Issuer)

    4/2/25 5:47:31 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    $VERO
    Financials

    Live finance-specific insights

    View All

    Venus Concept to Release Third Quarter of Fiscal Year 2025 Financial Results on November 13, 2025

    TORONTO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that third quarter of fiscal year 2025 financial results will be released before the market opens on Thursday, November 13, 2025. Management will host a conference call at 8:00 a.m. Eastern Time on November 13, 2025 to discuss the results of the quarter and host a question and answer session. Those who would like to participate may dial 877-407-2991 (+1 201-389-0925 for international callers) and provide access code 13756285. A live webcast of the call will also be provided on the investor relations section of the Com

    10/1/25 4:05:00 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    Venus Concept to Release Second Quarter of Fiscal Year 2025 Financial Results on August 14, 2025

    TORONTO, July 16, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that second quarter of fiscal year 2025 financial results will be released after the market closes on Thursday, August 14, 2025. Management will host a conference call at 5:00 p.m. Eastern Time on August 14, 2025 to discuss the results of the quarter and host a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13754867. A live webcast of the call will also be provided on the investor relations section of the Company's

    7/16/25 7:30:00 AM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    Venus Concept to Release First Quarter of Fiscal Year 2025 Financial Results on May 15, 2025

    TORONTO, April 07, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that first quarter of fiscal year 2025 financial results will be released before the market opens on Thursday, May 15, 2025. Management will host a conference call at 8:00 a.m. Eastern Time on May 15, 2025 to discuss the results of the quarter and host a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13753054. A live webcast of the call will also be provided on the investor relations section of the Company's websi

    4/7/25 7:30:00 AM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    $VERO
    Leadership Updates

    Live Leadership Updates

    View All

    Venus Concept Inc. Appoints Dr. Hemanth Varghese as President and Chief Operating Officer and Industry Veteran to Lead International Operations

    TORONTO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced the promotion of Dr. Hemanth Varghese to the newly created role of President and Chief Operating Officer (COO), reporting to Chief Executive Officer, Rajiv De Silva, effective October 16, 2023. Dr. Varghese joined Venus Concept in October of 2022 as President and Chief Business Officer. His responsibilities were later expanded to include the Chief Innovation Officer role as well. Dr. Varghese has been pivotal in developing and executing the Company's turnaround strategy. In his new role, Dr. Varghese will assume

    10/12/23 7:30:00 AM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    Venus Concept Appoints Dr. Hemanth Varghese as President & Chief Business Officer

    TORONTO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced the appointment of Dr. Hemanth Varghese to the position of President & Chief Business Officer, effective October 17, 2022. "We are delighted to have Hemanth join Venus Concept at this pivotal time for the Company," said Rajiv De Silva, Chief Executive Officer and Director of Venus Concept. "Hemanth is an accomplished healthcare executive with a 20-year track record of performance and execution. He is a versatile leader with experience leading diverse healthcare businesses in high-growth markets in North America and in

    10/11/22 7:30:00 AM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    Venus Concept Appoints Ross J. Portaro as President of Global Sales

    TORONTO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced the appointment of Ross J. Portaro to the position of President of Global Sales, effective October 15, 2021. Mr. Portaro will assume the responsibilities of Chad A. Zaring, who is resigning from his role of Chief Commercial Officer for personal reasons, effective October 15, 2021. Mr. Zaring will continue to support the Company as a consultant through March 31, 2022. "Ross is an accomplished leader and industry veteran with more than 30 years of experience in the healthcare sector, including positions at Candela Med

    10/12/21 7:30:00 AM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    $VERO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Venus Concept Inc.

    SC 13D/A - Venus Concept Inc. (0001409269) (Subject)

    10/8/24 7:51:38 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by Venus Concept Inc.

    SC 13D/A - Venus Concept Inc. (0001409269) (Subject)

    10/3/24 7:59:41 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Venus Concept Inc.

    SC 13G/A - Venus Concept Inc. (0001409269) (Subject)

    9/30/24 9:53:26 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care